Category Press Releases

Roche’s Gazyva Secures FDA Approval for Lupus, Marking Expansion Beyond Cancer

The FDA approval marks Gazyva’s first non-oncology indication, expanding Roche’s presence into autoimmune disease treatment. The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting…

Read MoreRoche’s Gazyva Secures FDA Approval for Lupus, Marking Expansion Beyond Cancer
EMD Serono

ME Therapeutics Licenses CD22 Nanobody to Advance In Vivo CAR Therapy Program

The agreement strengthens ME Therapeutics’ next-generation in vivo CAR cell therapy platform, expanding its pipeline targeting B-cell malignancies through innovative nanobody-based technologies. ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company…

Read MoreME Therapeutics Licenses CD22 Nanobody to Advance In Vivo CAR Therapy Program

Roche Showcases Breakthroughs in Sequencing by Expansion and Sets New World Record at ASHG 2025

Roche Showcases Breakthrough Sequencing by Expansion (SBX) Technology and Sets New GUINNESS WORLD RECORD™ at ASHG 2025 Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled a series of groundbreaking advancements in its Sequencing by Expansion (SBX) technology during the American Society…

Read MoreRoche Showcases Breakthroughs in Sequencing by Expansion and Sets New World Record at ASHG 2025

Taiho Pharma Licenses PI3Kα Inhibitor Risovalisib (CYH33) to Haihe Biopharma

Taiho Pharmaceutical Grants Exclusive Rights for PI3Kα Inhibitor Risovalisib (CYH33) to Haihe Biopharma Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an exclusive license agreement granting Taiho the rights to develop, manufacture,…

Read MoreTaiho Pharma Licenses PI3Kα Inhibitor Risovalisib (CYH33) to Haihe Biopharma

Zoetis Receives Health Canada Approval for Lenivia® to Treat Osteoarthritis Pain in Dogs

Zoetis Receives Health Canada Approval for Lenivia® to Relieve Osteoarthritis Pain in Dogs Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the treatment of pain associated with osteoarthritis (OA) in dogs. Lenivia, a novel monoclonal…

Read MoreZoetis Receives Health Canada Approval for Lenivia® to Treat Osteoarthritis Pain in Dogs

GSK’s Shingrix Receives Approval in China to Prevent Shingles in Immunocompromised Adults Aged 18 and Older

GSK’s Shingrix Receives Approval in China to Protect Immunocompromised Adults Against Shingles GSK plc (LSE/NYSE: GSK) today announced that the China National Medical Products Administration (NMPA) has granted approval for Shingrix—GSK’s Recombinant Zoster Vaccine (RZV)—for the prevention of shingles (herpes…

Read MoreGSK’s Shingrix Receives Approval in China to Prevent Shingles in Immunocompromised Adults Aged 18 and Older

DB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss

Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for its investigational gene therapy DB-OTO for profound genetic hearing loss…

Read MoreDB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss